Medicines Co (MDCO.OQ) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : S&P Capital IQ Quantitative Report
$115.00
Provider : Stock Traders Daily
$20.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medicines Co receives market authorization renewal for Angiox (Bivalirudin) from the European Medicines Agency and the European Commission


Monday, 7 Jul 2014 09:00am EDT 

Medicines Co:Announces that the European Medicines Agency (EMA), the Committee for Medicinal Products for Human Use (CHMP), and the European Commission have granted market authorization renewal for Angiox.Following a review of the latest clinical, safety, and efficacy data, as well as the Angiox risk management plan.Says the CHMP recommendation for the renewal of the marketing authorization for Angiox reconfirms its favorable risk-benefit profile.Angiox is a direct thrombin inhibitor and is indicated in Europe as an anticoagulant in adult patients undergoing percutaneous coronary intervention.